Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan

Environmental and Molecular Mutagenesis

Volumn 50, Issue 2, 2009, Pages 145-151

  Attia, Sabry M ^a,b   Aleisa, Abdulaziz M ^a   Bakheet, Saleh A ^a   Al Yahya, Abdulaziz A ^a   Al Rejaie, Salim S ^a   Ashour, Abdelkader E ^a,b   Al Shabanah, Othman A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Aneugen; Camptothecin; Carcinogen; Clastogen; FISH; Topotecan

Indexed keywords

ANEUGEN; CAMPTOTHECIN; CLASTOGEN; IRINOTECAN; TOPOTECAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SATELLITE DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CANCER RISK; CENTROMERE; CHEMICAL CARCINOGENESIS; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CONTROLLED STUDY; CYTOTOXICITY; DNA PROBE; DNA STRAND BREAKAGE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC DAMAGE; GENOTOXICITY; INDUCED MUTATION; MALE; MICRONUCLEUS TEST; MOUSE; MOUSE STRAIN; NONHUMAN; SWISS ALBINO MOUSE; ANIMAL; BONE MARROW; CHEMICALLY INDUCED DISORDER; CYTOGENETICS; DRUG EFFECT; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MICRONUCLEUS;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CAMPTOTHECIN; CYTOGENETICS; DNA PROBES; DNA, SATELLITE; IN SITU HYBRIDIZATION, FLUORESCENCE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; TOPOTECAN;

EID: 60849137884     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20460     Document Type: Article

References (49)

1. Adler I-D 1984.Cytogenetic tests in mammals. In:Venitt S, Parry JM, editors. Mutagenicity Testing: A Practical Approach. Oxford:IRI. pp. 275-306.
2. Armstrong DK, Spriggs D, Levin J, Poulin R, Lane S. 2005. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: An integrated analysis. Oncologist 10:686-694.
3. Attia SM. 2007. Chromosomal composition of micronuclei in mouse bone marrow treated with rifampicin and nicotine, analyzed by multicolor fluorescence in situ hybridization with pancentromeric DNA probe. Toxicology 235:112-118.
4. Attia SM, Kliesch U, Schriever-Schwemmer G, Badary OA, Hamada FM, Adler I-D. 2003. Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ Mol Mutagen 41:99-103.
5. Aydemir N, Bilaloglu R. 2003. Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat Res 537:43-51.
6. Backer LC, Allen JW, Harrington-Brock K, Campbell JA, DeMarini DM, Doerr CL, Howard DR, Kligerman AD, Moore MM. 1990. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Mutagen 5:541-547.
7. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. 2007. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28:625-631.
8. Cunha KS, Reguly ML, Graf U, De Andrade R, Helena H. 2002. Comparison of camptothecin derivatives, presently in clinical trials: Genotoxic potency and mitotic recombination. Mutagen 17:141-147.
9. De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F. 2001. Potent anti-tumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61:7189-7195.
10. Dhawan A, Kayani MA, Parry JM, Parry E, Anderson D. 2003. Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagen 18:487-490.
11. Garcia-Carbonero R, Supko JG. 2002. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661.
12. Garst J. 2007. Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert Opin Drug Saf 6:53-62.
13. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M. 1989. DNA-topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048.
14. Hardman WE, Moyer MP, Cameron IL. 1999. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: Doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res 19:2269-2274.
15. Hardman WE, Moyer MP, Cameron IL. 2002. Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 86:983-988.
16. Hartmann JT, Lipp HP. 2006. Camptothecin and podophyllotoxin derivatives: Inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 29:209-230.
17. Herzog TJ. 2002. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 7(Suppl 5):3-10.
18. Herzog TJ. 2003. Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol 90(3 Part 2):S3-S7.
19. Holmström M, Winters V. 1992. Micronucleus induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice. Mutagen 7:189-193.
20. Hsiang YH, Hertzberg R, Hecht S, Liu LF. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
21. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M. 1989. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4385-4389. Erratum in: Cancer Res 49:6868
22. Kliesch U, Danford N, Adler I.-D. 1981. Micronucleus test and bone-marrow chromosome analysis: A comparison of 2 methods in vivo for evaluating chemically induced chromosomal alterations. Mutat Res 80:321-332.
23. Li QY, Zu YG, Shi RZ, Yao LP. 2006. Review camptothecin: Current perspectives. Curr Med Chem 13:2021-2039.
24. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. 2000. Mechanism of action of camptothecin. Ann NY Acad Sci 922:1-10.
25. Mahabir AG, Benthem Jv, Korsten H, Lynch AM, Bailey L, de Vries A, Hendriksen CFM, Steeg Hv. 2008. Detecting genotoxic effects of potential clastogens: An in vivo study using the transgenic lacZ plasmid and the MutaTMMouse model. Mutat Res 652:151-157.
26. Mosesso P, Pichierri P, Franchitto A, Palitti F. 2000. Evidence that camptothecin-induced aberrations in the G(2) phase of cell cycle of Chinese hamster ovary (CHO) cell lines is associated with transcription. Mutat Res 452:189-195.
27. Nitiss L. 1994. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 29:103-134.
28. O'Brien M, Eckardt J, Ramlau R. 2007. Recent advances with topotecan in the treatment of lung cancer. Oncologist 12:1194-1204.
29. Orta ML, Mateos S, Cantero G, Wolff LJ, Cortés F. 2008. Protection of halogenated DNA from strand breakage and sister-chromatid exchange induced by the topoisomerase I inhibitor camptothecin. Mutat Res 637:40-48.
30. Osheroff N. 1998. DNA topoisomerases. Biochim Biophys Acta 1400:1-2.
31. Pommier Y. 2006. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 6:789-802.
32. Porter SE, Champoux JJ. 1989. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17:8521-8532.
33. Punt CJ, Koopman M. 2008. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol 26:1907-1908.
34. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. 2007. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13:1066-1072.
35. Sachs L. 1984. Angewandte Statistik, Auflage, Vol. 6. Berlin:Springer. pp 230-238.
36. Salamone MF, Mavournin KH. 1994. Bone marrow micronucleus assay: A review of the mouse stocks used and their published mean spontaneous micronucleus frequencies. Environ Mol Mutagen 23:239-273.
37. Sambrook J, Fritsch EF, Manitatis T. 1989. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, New York:Cold Spring Harbor Laboratory Press.
38. Schriever-Schwemmer G, Adler I-D. 1993. A mouse stock with 38 chromosomes derived from the reciprocal translocation T(7;15)33Ad. Cytogenet Cell Genet 64:122-127.
39. Schriever-Schwemmer G, Adler I-D. 1994. Differentiation of micronuclei in mouse bone marrow cells: A comparison between CREST staining and fluorescent in situ hybridization with centromeric and telomeric DNA probes. Mutagen 9:333-340.
40. Schriever-Schwemmer G, Kliesch U, Adler I-D. 1997. Extruded micronuclei induced by colchicine or acrylamide contain mostly lagging chromosomes identified in paintbrush smears by minor and major mouse DNA probes. Mutagen 12:201-207.
41. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. 1993. The current status of camptothecin analogs as antitumor agents. J Natl Cancer Inst 85:271-291.
42. Sortibrán AN, Téllez MG, Rodríguez-Arnaiz R. 2006. Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster. Mutat Res 604:83-90.
43. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. 2005. Camptothecin and its analogues: A review on their chemotherapeutic potential. Nat Prod Res 19:393-412.
44. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. 1994. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842.
45. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y. 1995. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34:7200-7206.
46. Wall ME, Wani MC. 1996. Camptothecin. Discovery to clinic. Ann NY Acad Sci 803:1-12.
47. Wang X, Wang LK, Kingsbury WD, Johnson RK, Hecht SM. 1998. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry 37:9399-9408.
48. Wong AKC, Rattner JB. 1988. Sequence organization and cytological localization of the minor satellite of mouse. Nucleic Acids Res 16:11645-11661.
49. Zunino F, Pratesi G. 2004. Camptothecins in clinical development. Expert Opin Invest Drugs 13:269-284.